Generic Medicine Info
Indications and Dosage
Adult: Initially, 5-10 mg in the morning, daily or on alternate days. Maintenance dose: 5-30 mg wkly in divided doses. Max: 20 mg daily.
Child: 1 mth to 2 yr 50-100 mcg/kg/day; >2-12 yr 50-400 mcg/kg/day (max of 10 mg), followed by 50-100 mcg/kg/day, adjusted according to response.

Suppression of lactation
Adult: 5 mg in the morning and 5 mg at midday for 5 days.

Adult: 2.5 mg in the morning daily, either alone or in conjunction w/ other antihypertensive. Max: 20 mg daily.
Child: 1 mth to 2 yr 50-100 mcg/kg/day; >2-12 yr 50-400 mcg/kg/day (max of 10 mg), followed by 50-100 mcg/kg/day, adjusted according to response.

Idiopathic hypercalciuria
Adult: 2.5 mg daily w/ increased fluid intake.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
May be taken with or without food. May be taken w/ food or milk.
Anuria, severe renal and hepatic impairment, symptomatic hyperuricaemia, Addison's disease. Refractory hypokalaemia, hyponatraemia, and hypercalcaemia.
Special Precautions
Patients w/ electrolyte imbalance, DM, gout, mild to moderate hepatic and renal impairment. May exacerbate SLE. Pregnancy and lactation.
Adverse Reactions
Electrolyte imbalance, gout, postural hypotension, GI effects, hyperglycaemia, altered plasma lipid concentration, rashes, photosensitivity, blood disorders, pancreatitis, intrahepatic cholestasis.
PO: C (FDA Pregnancy Category C applies to bendroflumethiazide in combination w/ nadolol.)
Symptoms: Anorexia, nausea, vomiting, diarrhoea, diuresis, dehydration, hypotension, dizziness, weakness, muscle cramps, paraesthesia, tetany, GI bleeding, hyponatraemia, hypo- or hyperglycaemia, hypokalaemia and metabolic alkalosis. Management: Initiate emesis or gastric lavage, if appropriate. Symptomatic and supportive treatment including correction of fluid and electrolyte imbalance. Monitor BP.
Drug Interactions
Increased serum levels of lithium. Increased nephrotoxicity of NSAID. Increased hypokalaemic effect w/ xanthines, beta-agonists, ACTH, corticosteroids, acetazolamide, carbenoxolone and reboxetine. Enhanced neuromuscular blocking effect of non-depolarising muscle relaxants (e.g. tubocurarine). Postural hypotension may be enhanced by barbiturates, opioids and TCA. Increased risk of hyponatraemia w/ carbamazepine, amphotericin and aminoglutethimide. Increased risk of nephrotoxicity and ototoxicity w/ cisplatin. Reduced absorption by colestipol and colestyramine. Increased risk of ventricular arrhythmias w/ pimozide, thioridazine and terfenadine.
Lab Interference
May interfere w/ PBI (protein-bound iodine) and parathyroid function tests.
Mechanism of Action: Bendroflumethiazide reduces the reabsorption of electrolytes from the renal tubules, thus increasing the excretion of Na and Cl ions and consequently of water. It also reduces the GFR.
Onset: Approx 2 hr.
Duration: 12-18 hr or longer.
Absorption: Completely absorbed from the GI tract. Time to peak plasma concentration: Approx 3-6 hr.
Distribution: Highly bound to plasma proteins.
Metabolism: Undergoes fairly extensive metabolism.
Excretion: Via urine (as unchanged drug). Plasma half-life: Approx 3-4 hr.
Store between 20-25°C. Protect from excessive heat.
MIMS Class
Anon. Thiazides General Statement. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc.

Buckingham R (ed). Bendroflumethiazide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/06/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Bendroflumethiazide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 04/06/2014.

Disclaimer: This information is independently developed by MIMS based on Bendroflumethiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in